Table 1.
Candidate Gene Studies from STAR*D and Genome-wide Association Studies of Treatment Responses to Antidepressants.
| Author (Year) | Drug | Gene(s) | Outcome | Sample Size | Key Finding(s) |
|---|---|---|---|---|---|
| Candidate gene studies from STAR*D | |||||
| McMahon (2006) | Citalopram | 68 genes | Efficacy | 1,953 (split sample design) | Association with 5-HTR2A |
| Hu (2007) | Citalopram | 5-HTT | Efficacy Remission Tolerance Adverse effects |
1,775 | Association with adverse effect burden |
| Kraft (2007) | Citalopram | 5-HTT | Efficacy | 1,914 | No association |
| Paddock (2007) | Citalopram | 68 genes | Efficacy | 1,816 (full sample) | Association with GRIK4 |
| Peters (2008) | Citalopram | CYP2D6, CYP2C19, CYP3A4, CYP3A5, ABCB1 | Efficacy Tolerance |
1,953 (split sample design) | No associations |
| Lekman (2008) | Citalopram | FKBP5 | Efficacy | 1,809 | Association with response |
| Cabanero (2009) | Citalopram | PDE11A, PDE1A, PDE9A | Efficacy | 1,914 | No association |
| Domschke (2009) | Citalopram | BDNF | Efficacy | 1,914 | No association |
| Perlis (2009) | Citalopram | 68 genes | Sexual Dysfunction | 1,473 | Associations with GRIA3, GRIK2, GRIA1, GRIN3A |
| Genome-wide association studies | |||||
| Laje (2009) | Citalopram | Illumina Human-1 Bead Chip |
Treatment emergent suicidal ideation | 180 | Association with PAPLN |
| Garriock (2009) | Citalopram | Affymetrix 500K and 5.0 | Efficacy | 1,491 | Suggestive associations with UBE3C, BMP7, RORA |
| Ising (2009) | Antidepressants | Illumina Human-1 and HumanHap300 Bead Chips |
Efficacy | 339 | Association with a multifactorial SNP score |